Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05594069
Other study ID # Pre-rehabilitation
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 24, 2022
Est. completion date October 30, 2023

Study information

Verified date November 2023
Source Peking University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the intervention effect of triple pre-rehabilitation on head and neck cancer patients with radiotherapy, and process evaluation to further optimize the intervention program. The pre-rehabilitation intervention was develped previously based on the process of evidence-based-nursing, including interventions of nurtrtion, exercise, and psychology.


Recruitment information / eligibility

Status Completed
Enrollment 87
Est. completion date October 30, 2023
Est. primary completion date July 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - 18= age < 75 years old - The pathological diagnosis of HNC included nasopharyngeal cancer, oral cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, salivary gland cancer; - Plan to receive radiotherapy - Basic communication skills - Volunteer to participate in this study. Exclusion Criteria: - Combined with other malignant tumors - Distant metastasis - Inability to measure body composition, such as metal in the body or inability to stand alone - With contraindications to exercise (such as cardiovascular and cerebrovascular diseases, respiratory diseases, etc) - Complicated with severe liver and kidney function damage - Previous diagnosis of other cancers - pregnant or lactation women.

Study Design


Intervention

Other:
triple pre-rehabilitation
The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
triple rehabilitation
The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.

Locations

Country Name City State
China Tianjin medical university cancer institute and hospital Tianjin

Sponsors (2)

Lead Sponsor Collaborator
Peking University China International Medical Foundation

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Critical weight loss Weight loss over 5% during radiotherapy About 6 weeks
Secondary Rate of adverse reactions of radiotherapy assessed by CTCAE v5.0 Adverse reactions of radiotherapy About 6 weeks
Secondary Physical performance Physical performance measured by the 4-Meter Walk Test About 6 weeks
Secondary Physical performance Physical performance measured by 30-Second Chair Stand Test (30-SCST) About 6 weeks
Secondary Physical performance Physical performance measured by hand grip strength About 6 weeks
Secondary Body composition measured by Bioelectrical Impedance Analysis (BIA) Body composition measured by Bioelectrical Impedance Analysis (BIA) About 6 weeks
Secondary Quality of life of patients assessed by QLQ-C30 Quality of life of patients assessed by QLQ-C30 About 6 weeks
Secondary Intake assessed by a simple diet self-assessment tool (SDSAT) Intake assessed by a simple diet self-assessment tool (SDSAT) About 6 weeks
Secondary Psychological status assessed by hospital anxiety and depression scale (HADS) Psychological status assessed by hospital anxiety and depression scale (HADS) About 6 weeks
Secondary Number of participants with intervention-related adverse events Number of participants with intervention-related adverse events About 6 weeks
Secondary Patients in the intervention group were interviewed about the compliance of the study Patients in the intervention group were interviewed about the compliance of the study About 6 weeks
Secondary Patients in the intervention group were interviewed about the experience of the study Patients in the intervention group were interviewed about the experience of the study About 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Completed NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2